• About us
• Contact

Advertisement

Organisation › Details

Allcyte GmbH

Allcyte is a Vienna, Austria-based precision medicine company whose mission is to ensure that every cancer patient gets the best possible treatment. Allcyte’s technology is designed to select the most promising drug candidates for clinical development in the right patient populations to maximize clinical study success rates and patient bene?t. Clinically, Allcyte’s goal is to provide physicians with actionable insights on how to treat cancer patients with the right drug at the right time in situations where classical genetics-driven precision medicine does not give precise answers. This is achieved by measuring functional anticancer drug activity in viable, primary human patient tissues at the single cell resolution to gain a preview of likely clinical ef?cacy. Allcyte’s technology is the first AI platform to successfully improve cancer patient outcomes in a clinical trial. *

 

	Start	2016-12-12 established (s-off)
	Group	Exscientia (Group)
	Predecessor	Ce-M-M-Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
	Industry	personalised medicine / precision medicine
	Industry 2	artificial intelligence (AI) / machine learning (ML)
	Person	Krall, Nikolaus (Allcyte 202106 CEO)
	Region	Wien (Vienna)
	Country	Austria
	Street	14 Lazarettgasse AKH 25.3
	City	1090 Wien
	Tel	+43-676-9271943
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Exscientia Ltd.. (6/15/21). "Press Release: Exscientia Acquires Personalised Medicine AI Pioneer Allcyte".
		Record changed: 2021-06-16

Advertisement

More documents for Exscientia (Group)

• [1] Exscientia plc. (10/3/23). "Press Release: Exscientia Details Pipeline Prioritisation Strategy". Oxford....
• [2] Merck KGaA. (9/20/23). "Press Release: Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery [Not intended for US-, Canada- or UK-based media]". Darmstadt....
• [3] Exscientia plc. (9/20/23). "Press Release: Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany". Oxford....
• [4] Exscientia plc. (3/7/23). "Press Release: Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform". Oxford & Berlin....
• [5] Exscientia plc. (11/3/22). "Press Release: Exscientia Expands Biologics Design Capability with Automated Laboratory". Oxford....
• [6] Exscientia Ltd.. (8/4/21). "Press Release: Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline"....
• [7] Exscientia Ltd.. (6/15/21). "Press Release: Exscientia Acquires Personalised Medicine AI Pioneer Allcyte"....
• [8] Allcyte GmbH. (3/25/21). "Press Release: Austrian Biotech Allcyte Raises $6m Seed Round Following Breakthrough Cancer Clinical Trial"....
• [9] Exscientia Ltd.. (1/5/21). "Press Release: Exscientia Appoints Richard Law to Expand Its AI-drug discovery Partnering Business"....
• [10] Exscientia Ltd.. (9/29/20). "Press Release: Exscientia Appoints Industry R&D Veteran, David Nicholson, as Chairman as Company Extends Pipeline"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.